Objective: To investigate the effect of SLC6A8 on the proliferation of liver cancer cells by regulating mitophagy through BNIP3L. Methods: The expression of the SLC6A8 gene in liver cancer tissues was analyzed using t...Objective: To investigate the effect of SLC6A8 on the proliferation of liver cancer cells by regulating mitophagy through BNIP3L. Methods: The expression of the SLC6A8 gene in liver cancer tissues was analyzed using the TCGA database, and its correlation with BNIP3L expression was assessed. RT-PCR and Western blot techniques were employed to detect the expression of SLC6A8 and BNIP3L in human liver cancer Huh-7 and Hep3B cells. Immunofluorescence labeling and CCK-8 assay were used to observe mitochondrial autophagy and cell proliferation rate in SLC6A8-overexpressing Huh-7 and Hep3B cells. Evaluate the proliferation rate of SLC6A8-overexpressing Huh-7 and Hep3B cells after silencing BNIP3L using the CCK-8 detection method. Results: SLC6A8 was significantly overexpressed in liver cancer tissues and positively correlated with BNIP3L expression. Overexpression of SLC6A8 significantly promoted mitochondrial autophagy and proliferation of Huh-7 and Hep3B cells. Additionally, SLC6A8 overexpression significantly enhanced the expression of BNIP3L mRNA and protein. Upon BNIP3L silencing, the proliferative effect of SLC6A8 overexpression on liver cancer cells was reversed. Conclusion: High expression of SLC6A8 in liver cancer tissues is positively correlated with BNIP3L, and overexpression of SLC6A8 promotes mitochondrial autophagy and liver cancer cell proliferation. Silencing BNIP3L can reverses the effect of overexpression of SLC6A8 on liver cancer cell proliferation. This provides new targets and strategies for the treatment of liver cancer.展开更多
目的应用同位素标记相对与绝对定量蛋白组学(isobaric tags for relative and absolute quantification,iTRAQ)技术鉴定和筛选特发性膜性肾病(idiopathic membranous nephropathy,IMN)患者外周血中的差异蛋白,验证IMN患者差异蛋白S100A...目的应用同位素标记相对与绝对定量蛋白组学(isobaric tags for relative and absolute quantification,iTRAQ)技术鉴定和筛选特发性膜性肾病(idiopathic membranous nephropathy,IMN)患者外周血中的差异蛋白,验证IMN患者差异蛋白S100A8表达水平及其意义。方法收集IMN组、非膜性肾病组(not-idiopathic membranous nephropathy,NIMN)和健康对照组的外周血标本,结合生物信息学分析获得差异表达蛋白。采用蛋白质免疫印迹(Western Blot,WB)及酶联免疫吸附方法(ELISA法)检测S100A8蛋白在3组的表达,分析其表达与IMN的关系。结果①通过iTRAQ方法并结合生物信息学分析筛选出S100A8作为目标蛋白;②S100A8在30例IMN患者中表达增高,与NIMN组差异有统计学意义(P<0.001);③ROC曲线显示S100A8蛋白对IMN有高诊断价值。结论检测S100A8蛋白的表达对诊断IMN具有一定价值,S100A8可能是IMN的候选生物标志物。展开更多
基金Research Fund for Young and Middle-aged Teachers'Basic Research Ability Promotion Project of Guangxi Universities in 2021(No.2021KY0539)。
文摘Objective: To investigate the effect of SLC6A8 on the proliferation of liver cancer cells by regulating mitophagy through BNIP3L. Methods: The expression of the SLC6A8 gene in liver cancer tissues was analyzed using the TCGA database, and its correlation with BNIP3L expression was assessed. RT-PCR and Western blot techniques were employed to detect the expression of SLC6A8 and BNIP3L in human liver cancer Huh-7 and Hep3B cells. Immunofluorescence labeling and CCK-8 assay were used to observe mitochondrial autophagy and cell proliferation rate in SLC6A8-overexpressing Huh-7 and Hep3B cells. Evaluate the proliferation rate of SLC6A8-overexpressing Huh-7 and Hep3B cells after silencing BNIP3L using the CCK-8 detection method. Results: SLC6A8 was significantly overexpressed in liver cancer tissues and positively correlated with BNIP3L expression. Overexpression of SLC6A8 significantly promoted mitochondrial autophagy and proliferation of Huh-7 and Hep3B cells. Additionally, SLC6A8 overexpression significantly enhanced the expression of BNIP3L mRNA and protein. Upon BNIP3L silencing, the proliferative effect of SLC6A8 overexpression on liver cancer cells was reversed. Conclusion: High expression of SLC6A8 in liver cancer tissues is positively correlated with BNIP3L, and overexpression of SLC6A8 promotes mitochondrial autophagy and liver cancer cell proliferation. Silencing BNIP3L can reverses the effect of overexpression of SLC6A8 on liver cancer cell proliferation. This provides new targets and strategies for the treatment of liver cancer.